[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610487":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":27,"centralContacts":32,"locations":42,"responsibleParty":64,"collaborators":68,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":21,"enrollmentInfo":82,"targetDuration":21,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":45,"whyStopped":21,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Wills Eye","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Surgery for patients with medically uncontrolled POAG","EXPERIMENTAL","surgery using combined minimally invasive surgical iStent infinite trabecular micro-bypass systme model iS3 and drug depot iDose TR (Travoprost Intracameral Implant) 75mcg",[13,14],"Device: iStent infinite trabecular micro-bypass system model iS3","Drug: iDose TR (Travoprost intracameral Implant) 75mcg",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DEVICE","iStent infinite trabecular micro-bypass system model iS3","surgery perfomed using the iStent infinite trabecular micro-bypass system model iS3",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"DRUG","iDose TR (Travoprost intracameral Implant) 75mcg","surgery performed using the iDose TR (Travoprost intracameral Implant) 75mcg",[9],[28],{"name":29,"affiliation":30,"role":31},"Dilru Amarasekera, MD","Wills Eye Hospital Glaucoma Research","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":21,"email":37},"Meskerem Divers","CONTACT","215-825-4712","mdivers@willseye.org",{"name":39,"role":35,"phone":40,"phoneExt":21,"email":41},"Jeanne L Molineaux, COA","215-825-4713","jmolineaux@willseye.org",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Wills Eye Hosital Glaucoma Dept.","RECRUITING","Philadelphia","Pennsylvania","19107","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-75.16362,39.95238,{"lat":55,"lon":54},[58,60,63],{"name":34,"role":35,"phone":59,"phoneExt":21,"email":37},"(215)825-4712",{"name":61,"role":35,"phone":62,"phoneExt":21,"email":41},"Jeanne Molineaux, COA","(215)825-4713",{"name":29,"role":31,"phone":21,"phoneExt":21,"email":21},{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"SPONSOR_INVESTIGATOR","Jonathon Myers","Co-Investigator",[69],{"name":70,"class":71},"Glaukos Corporation","INDUSTRY","100610487","phase-4-standalone-istent-infinite-and-idose-tr-for-management-of-moderate-to-severe-open-angle-glaucoma-100610487",false,"NCT07228221","Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma","iStent Infinite and iDose TR for Management of Moderate to Severe Primary Open Angle Glaucoma Are a Safe and Effective Alternative to Filtering Surgery for IOP Reduction in Patients With Medically Uncontrolled Glaucoma. (POAG)","POAG","Inclusion Criteria:\n\n* Moderate to severe open angle glaucoma (including POAG, PG, and PXG)\n* Open angle configuration (Shaffer grade ≥ 3), normal angle anatomy9\n* Visual acuity HM or better\n* VF MD -6dB or worse\n* Failed medical therapy and\u002For laser treatment\n* Incisional glaucoma surgery contemplated as next intervention\n* Phakic or pseudophakic\n\nExclusion Criteria:\n\n* Traumatic, uveitic, neovascular glaucoma, or angle closure glaucoma\n* Previous incisional glaucoma surgery\n* ALT; History of iridotomy, SLT, or micropulse laser trabeculoplasty within the prior 90 days\n* Active ocular inflammation or edema, clinically significant corneal dystrophy\n* Corneal or other pathology preventing accurate Goldmann applanation tonometry","ALL","18 Years",{"count":83,"type":84},20,"ESTIMATED","INTERVENTIONAL",[87],"PHASE4","The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.",[90,91,92],"Open Angle Glaucoma","Pigmentary Glaucoma","Pseudoexfoliation Glaucoma",[78,94,95],"PG","PXG","2025-11-13",{"date":98,"type":99},"2025-11-14","ACTUAL",{"date":101,"type":84},"2026-01-05",{"date":103,"type":84},"2031-12-31",{"name":66,"class":6},1]